<DOC>
	<DOCNO>NCT00811096</DOCNO>
	<brief_summary>Assess efficacy 2 grams tinidazole give 5 day standard dose chloroquine achieve radical cure Plasmodium vivax within 90 day follow-up period sufficient justify IND formal phase II evaluation .</brief_summary>
	<brief_title>Pilot Human Study Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax</brief_title>
	<detailed_description>This randomize , open-label study treat adult subject Plasmodium vivax infection chloroquine 3 day tinidazole 5 day concomitantly assess efficacy radical cure ( clearance blood liver stage infection ) . There randomization positive comparator arm treat chloroquine primaquine ( definitive radical cure ) order obtain estimate rate re-infection monitoring period study population . A simple randomization procedure assign subject one two arm ( treatment arm comparator arm ) . The ratio assignment 2:1 , treatment arm comparator arm . The exact number assign treatment arm vary depend initial outcome early enrollee per sequential analysis design trial . In bad case scenario clear trend develop early , 50 subject require complete trial study drug arm order arrive conclusion regard study drug . Follow-up period 90 day . This allow u capture essentially early relapse would occur normal circumstance , well assess tinidazole may delay fully eliminate recurrence . Subjects without recurrence 90 day consider achieved radical cure . This study use modify triangular test , form sequential analysis design enable repeat statistical analysis throughout study recruitment period , maintain pre-specified power type I error . The trial stop soon information accumulate consider sufficient reach conclusion limit enrollment exposure fail treatment regimen . Results study sufficient determine whether tinidazole designate `` early kill '' ( ineffective drug vivax malaria radical cure future evaluation ) whether sufficiently efficacious warrant investment IND formal phase II study seek SNDA .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Tinidazole</mesh_term>
	<criteria>Adult male nonpregnant female volunteer communicate Burmese Karen language . Age : Between 18 65 year ( inclusive ) . Acute , symptomatic , blood smear positive diagnosis Plasmodium vivax monoinfection . Ability comprehend comply requirement protocol . Willing provide write informed consent . Willing abstain alcohol ( EtOH ) use initial treatment 72 hour thereafter . Sexually active female must test negative urine pregnancy test must counsel effective method avoid pregnancy ( e.g. , intrauterine contraceptive device ; oral contraceptive ; diaphragm condom combination contraceptive jelly , cream foam ; Norplant® DepoProvera® ) , surgically sterile , postmenopause least one year , monogamous sterile sexual partner least 15 day prior dose study product least 72 hour last dose test drug . Subjects positive G6PD deficiency . Pregnant woman ( clinically positive urine βHCG ) nursing mother . Concomitant use metronidazole , albendazole mebendazole . Any malaria treatment use azithromycin macrolides , tetracycline , sulfonamide , doxycycline , tetracycline sulfa base drug antimalarial activity previous 4 week prior screen . Additionally , concomitant use phenobarbitol , rifampin , phenytoin , fosphenytoin , cimetidine , ketoconazole , cholestryramine constitute exclusion criterion . Significant health problem , include , limited significant , cardiac , renal liver disease lab abnormalities subject suspect abstain alcohol use treatment subsequent 3 day . Mixed malaria infection admission determine malaria smear and/or positive HRP2 antigen test . A previous history significant intolerance hypersensitivity study drug tinidazole chloroquine primaquine . ( nausea alone previous primaquine use exclude factor unless subject unable complete primaquine course due discomfort . ) Subjects receive transfusion within previous 30 day . Presenting hematocrit &lt; 25 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Malaria , Vivax/*drug therapy</keyword>
	<keyword>Tinidazole/pharmacology/*therapeutic use</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Plasmodium vivax/*drug effect</keyword>
</DOC>